Clinical Trials Logo

Autoimmune Thrombocytopenia clinical trials

View clinical trials related to Autoimmune Thrombocytopenia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04902807 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

ATRACTion
Start date: June 2021
Phase:
Study type: Observational

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

NCT ID: NCT04070599 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

IMMUNOTI
Start date: April 12, 2011
Phase: Phase 3
Study type: Interventional

This study aims to determine the hemato-immunological parameters predictive of the evolution of a Immune thrombocytopenic purpura (ITP) towards chronicity, and to identify possible differences between the child and the adult.

NCT ID: NCT03421184 Completed - Clinical trials for Rheumatoid Arthritis

Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus

ISOLED
Start date: November 26, 2018
Phase: N/A
Study type: Interventional

The study aims at determining if dietary phytoestrogens can be risk factors for Systemic Lupus Erythematosus (SLE). Dietary enquiry and phytoestrogens measurements will be performed in blood and urine of patients with SLE in an active phase of the disease, in patient with other autoimmune diseases and in healthy volunteers. Subjects will be premenopausal women and when possible at a define stage of the menstrual cycle. Free blood estradiol will be assayed as a confounding risk factor.

NCT ID: NCT01667263 Completed - Clinical trials for Autoimmune Thrombocytopenia

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Start date: June 1, 2012
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.

NCT ID: NCT01610180 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Start date: June 2012
Phase: Phase 2
Study type: Interventional

With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95% CI 27-72). Eltrombopag which has proved very effective in primary ITP could be effective also in ITP secondary to LPDs. This novel ITP specific treatment might spare these patients not only from bleeding risk but also from toxic or inappropriate cytotoxic therapies, not otherwise demanded by the burden of the underlying disease.

NCT ID: NCT01101295 Recruiting - Clinical trials for Purpura, Thrombocytopenic, Idiopathic

The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.

ITP-RITUX
Start date: April 2010
Phase: N/A
Study type: Observational

The primary purpose of the study is to describe by a prospective observational study the serious adverse events occurring in patients treated off-label by rituximab for Immune Thrombocytopenia.